XML 20 R9.htm IDEA: XBRL DOCUMENT

Other Income	6 Months Ended
Mar. 31, 2022
Other Income
Other Income	Note 3 Other Income Grant Income During the year ended September 30, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX^®2-73 related to Parkinson’s disease. The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the three and six months ended March 31, 2022, the Company did not recognize any of this grant on its statements of operations (2021: $10,820 and $10,820, respectively). At March 31, 2022, an amount of $443,831 (September 30, 2021: $443,831) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of operations as the relating expenditures are incurred to offset the income. Research and development incentive income Research and development incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit, (the “R&D Incentive Credit”). During the three and six months ended March 31, 2022 the Company recorded research and development incentive income of $835,513 (AUD 1,146,955) and $1,646,243 (AUD 2,263,317) (2021: $960,879 (AUD 1,244,133) and $2,230,195 (AUD 2,980,095)), respectively, related to the R&D Incentive Credit for eligible research and development expenses incurred during the period.

Other Income

6 Months Ended

Mar. 31, 2022

Note 3 Other Income

Grant Income

During the year ended September 30, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX^®2-73 related to Parkinson’s disease.

The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the three and six months ended March 31, 2022, the Company did not recognize any of this grant on its statements of operations (2021: $10,820 and $10,820, respectively). At March 31, 2022, an amount of $443,831 (September 30, 2021: $443,831) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of operations as the relating expenditures are incurred to offset the income.

Research and development incentive income

Research and development incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit, (the “R&D Incentive Credit”).

During the three and six months ended March 31, 2022 the Company recorded research and development incentive income of $835,513 (AUD 1,146,955) and $1,646,243 (AUD 2,263,317) (2021: $960,879 (AUD 1,244,133) and $2,230,195 (AUD 2,980,095)), respectively, related to the R&D Incentive Credit for eligible research and development expenses incurred during the period.